CStone Pharma, a Suzhou oncology company, signed an agreement with Suzhou Industrial Park to build a 100,000 square meter facility that will house integrated R&D, pilot plant and commercial manufacturing operations. The SIP provided support for the facility, which is expected to break ground in 2020. When completed, the complex will have a production capacity of 26,000L for large molecule biologics and 1 billion tablets and capsules for small molecule drugs. CStone claims to be the only China pharma with all three checkpoint inhibitors -- PD-1, PD-L1 and CTLA-4 -- in clinical development. More details....
Stock Symbol: (HKEX: 2616)
Share this with colleagues:
Original Article: CStone to Build Major R&D and Manufacturing Complex in Suzhou Park